ANSI Anti-Trust Policy:  Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).

Meeting Notes

• 8/18 - ObservationDefinition.qualifiedInterval.condition 
  • Zulip chat: https://chat.fhir.org/#narrow/stream/179256-Orders-and-Observation-WG/topic/ObservationDefinition.2EqualifiedInterval.2Econdition
  • Rahul Agarwal will attend to discuss.
  • Two issues:
    • ?? (missed that)
    • Observation.interpretation value set not able to align with ObservationDefinition.qualifiedInterval to indicate for the observation definition which values in observation interpretation code system
      • We need to enhance the qualifiedInterval backbone to address both valid reference ranges (numeric and qualitative) and associated interpretations from the larger observation interpretation code code system.
      • Rahul will provide a JIRA with a suggestion on how to enhance ObservationDefinition.qualifiedValue to reflect both needs more complete and more clear.

--------Backlog of Topics---------

• DiagnosticReport.status
  
  • Zulip chat: https://chat.fhir.org/#narrow/stream/179256-Orders-and-Observation-WG/topic/DiagnosticReport.20statuses.20and.20CLIA.20requirements.3F

  • Status in FHIR: http://hl7.org/implement/standards/fhir/codesystem-diagnostic-report-status.html

  • v2-FHIR Mapping Spreadsheet: HL7 Concept Map: ResultStatus[Non-Queries] - Google Sheets
  • 8/4 - Summarized the discussion from OO Main call and ran out of time. 
    • See links in Chat below
    • Still need a bit of clarification
    • Reviewed CAP Checklist from 2023
      • Corrected/correction - A change in a previously issued clinical pathology test report intended to correct an
        inaccuracy, including changes in test results, patient identification, reference intervals, interpretation, or other
        content.
•  Micro
  • Craig's v2 micro question: https://confluence.hl7.org/pages/viewpage.action?pageId=161080303#id-20230518Main-Subject:"v2discretemicroquestion"-Listservemessage(fromCraig)
  • The OBX-30 Observation Sub-Type Enhancements - Orders & Observations - Confluence (hl7.org) was created, and as it was created identified that various values were actually deleted, and examples were available for most but not all sub-types.
  • We reviewed the current wording and examples and updated the page with suggested adjustments (in red for text not in the published version and strikethrough where text is suggested to be removed)
  • Craig updated the example (Micro Example) using only the active/new values.
  • Open questions for next week:
    • Any other updates to the definitions/descriptions to clarify?
    • Any examples that would primarily be using MOD?
    • Any examples that could use either use MID or MOD?  We discussed PCR, but that raised questions whether is actually confusing and would require further explanation as for some it would never be used with MID.
    • Andrea had suggested that a more complex example she described would be helpful, but a volunteer to create that has not yet been identified.
    • No update
• Panel/Micro and discoverable Observations in FIHR
  • Hans/Fran to create an initial proposal, focusing on the micro scenario, on how to approach this in FHIR / FHIR US Core.
    • No update

• Other JIRAs from Triage Inventory - Not discussed

Chat History

Andrea Pitkus, PhD, MLS(ASCP)CE, FAMIA. UW-Madison to Everyone (Aug 18, 2023, 1:33 PM)
https://www.mayocliniclabs.com/test-catalog/overview/602753#Clinical-and-Interpretive
https://www.labcorp.com/tests/004226/testosterone-total
Testosterone test example w ref ranges based on age and sex

Andrea Pitkus, PhD, MLS(ASCP)CE, FAMIA. UW-Madison to Everyone (Aug 18, 2023, 1:45 PM)
you may want to compare observation.deifinition vs observation in FHIR side by side as they do differ.
definition is for any patient getting a test done.  whereas observation is for the specific pt instance.
(which I think folks recognize already)
Interested in Kathy's response too

Andrea Pitkus, PhD, MLS(ASCP)CE, FAMIA. UW-Madison to Everyone (Aug 18, 2023, 1:49 PM)
The value set with pre-follicular, et al may apply for the FSH results but not others:  https://www.mayocliniclabs.com/test-catalog/overview/602753#Clinical-and-Interpretive
Reference range is usually set up in tables in LIS associated with each result
so when a value comes across from instrument, then the applicable range is applied.  Interpretation for critical values or h ol can be applied
or low
The LIS set up has been historically separate from HL7 messaging.  However with your situation you are fulfilling both functions

V2 Lab JIRAs (link)

The following JIRA Tickets need to be reviewed by the Lab members as carry over from May 2023 WGM:

• V2-25376 - As soon as Dan has proposal.

FHIR Lab JIRA (link)

The following JIRA Tickets need to be reviewed by the Lab members as carry over from May 2023 WGM:

• FHIR-32406
• FHIR-32405
• FHIR-33041
• FHIR-34205
• FHIR- 32154 - Pending outcome of DiagnosticReport/Observation/Panel discussions